Justice Department substituting civil settlement for criminal Abbott probe

Summary

Department of Justice leadership replaced a contemplated criminal indictment of Abbott Laboratories with a civil settlement, applying a May 2025 executive order that restricts criminal sanctions to cases causing substantial public harm.
Abbott Laboratories secured finality against individual and corporate criminal charges while accepting civil allegations of a “culture of concealment” at its Sturgis baby formula plant.
Department leadership declined strong evidentiary records generated by the consumer-protection office under the new enforcement threshold.
State attorneys general and future federal prosecutors face a fragmented enforcement landscape as the federal retreat from criminal food-safety charges shifts deterrence calculations for corporate compliance.

The Justice Department closed its criminal investigation into Abbott Laboratories over conditions at a Michigan baby formula plant, substituting a civil settlement for a contemplated indictment that some prosecutors believed was supported by strong evidence. The decision, formalized through a multistate civil lawsuit filed in November, follows a May 2025 executive order restricting criminal sanctions to cases involving substantial public harm and reflects a broader departmental preference for resolving corporate compliance failures through financial clawbacks rather than criminal prosecution.

The Doctrinal Shift and Executive Directive

The closure of the criminal probe operationalizes a policy shift established by President Trump’s May 2025 executive order, which called for minimizing the use of criminal sanctions where civil penalties could be used instead. The White House directed at the time that prosecution should be reserved for cases in which companies or people “willingly choose not to comply, thereby causing or risking substantial public harm.” A Justice Department spokeswoman confirmed that the executive order guided the decision to close the criminal investigation, stating that criminal charges would have been “heavy-handed” and that officials instead resolved their concerns through a related civil lawsuit. “Ensuring the safety of our nation’s food supply is a top priority for the Trump administration, however, this Department of Justice does not believe in regulation by prosecution,” the spokeswoman said.

Acting Attorney General Todd Blanche has articulated a documented conduct standard that aligns with this directive. Blanche has stated he supports penalizing companies when prosecutors also can identify and charge people behind the wrongdoing, and he has criticized going after companies when prosecutors do not have enough evidence to charge individuals, or pursuing cases that do not appear to be winnable at trial. Blanche has been nominated by Trump to the permanent position, and senators are expected to press him about his views on enforcement during a confirmation hearing next month.

The Evidentiary Record and Civil Allegations

The criminal investigation was built on a substantial evidentiary record regarding conditions at the Sturgis facility. FDA inspectors in early 2022 found traces of the bacteria cronobacter sakazakii at the plant, including on equipment very close to infant formula containers, as well as standing water in multiple locations and employees who worked directly with baby formula but did not adequately wash their hands. The company had found the bacteria repeatedly in prior years. A former FDA official later testified to Congress that five different strains of the bacteria had been found at the plant, calling the facility “out of control.” Cronobacter infections sickened four babies who drank Abbott formula produced at the plant, two of whom died.

Abbott Laboratories denied a link between the plant’s conditions and the children who fell ill. The company noted that genetic testing by the Centers for Disease Control and Prevention found that the bacteria that infected two of the infants were not closely genetically linked to samples found at the plant, and a company spokesman stated that no unopened, distributed Abbott infant formulas have tested positive for the bacteria. Despite this, FDA officials told lawmakers that the cronobacter found in the plant remains a “serious concern” because such facilities are one of the most likely sources of contaminated formula.

While the criminal probe was closed, the underlying conduct survived in the civil record. The Justice Department said in November, as part of the related civil lawsuit joined by 31 states, that Abbott “knowingly” failed to follow manufacturing standards to protect against the risk of contamination. The suit alleged that Abbott had a “culture of concealment” at Sturgis and “withheld information from FDA related to the presence of microorganisms in the Sturgis facility.” The department and Abbott have reached a settlement to resolve that case, which was disclosed to a court last month, though the terms were not revealed.

Who Benefits from the Civil Resolution

The architecture of the resolution distributes distinct advantages and institutional costs across the involved parties. Department of Justice leadership gains alignment with the May 2025 executive order’s preference and, per Acting Attorney General Blanche’s stated view, avoids the trial risk of a case where individual charges were contested. Abbott Laboratories gains finality: the settlement forecloses the indictment exposure that the contemplated Food, Drug and Cosmetic Act misdemeanor count, the count for misleading the government, and at least one individual charge would have presented.

The 31 state attorneys general preserved their civil channel and a settlement framework that survives the criminal closure. Victims’ families, who were not parties to the criminal investigation, retain their civil claims. Conversely, the consumer-protection office lost a marquee case, and its institutional argument for retaining criminal authority is structurally weakened. The defense bar gains a precedent: a high-profile food-safety matter in which a strong evidentiary record produced by the consumer-protection office was effectively declined by department leadership.

Negotiation Dynamics and Structural Leverage

The resolution did not emerge from a purely integrative search for mutual gain; the rules of engagement were shifted by one party prior to final negotiations. The Department of Justice’s alternative to a negotiated agreement was to proceed with criminal charges, risking a loss at trial if the evidentiary standard for individual culpability could not be met while defying the executive directive. Abbott Laboratories’ alternative was to litigate the criminal charges aggressively, risking a devastating conviction and the precedent it would set. Both parties selected their respective civil pathways to cap exposure.

The leverage exercised in this resolution occurred not at the negotiation table but in the architectural design of the enforcement mechanism. The executive order functioned as a structural advantage rather than only a procedural guideline. The Department of Justice’s objective criteria relied on the Food, Drug and Cosmetic Act’s misdemeanor provisions and FDA inspection reports. Abbott’s objective criteria relied on the CDC’s genetic testing to sever the causal chain between plant conditions and infant injuries, and the May 2025 executive order as the controlling procedural standard.

The defense bar actively participated in shaping this structural advantage. Abbott’s defense lawyers included Mark Filip, who served as deputy attorney general under President George W. Bush. According to people familiar with those discussions, Filip urged the Justice Department to overhaul the consumer-focused office that steered the investigation and to remove its ability to bring criminal cases. The criminal closure of a high-profile food-safety matter strengthens this institutional position: the consumer-protection office now has a recent, prominent case in which its prosecutorial theory was effectively declined by department leadership, even as some of its prosecutors and supervisors described the evidence as strong.

Industry and external voices highlight the deterrent impact of the removed criminal leverage. Bill Marler, a lawyer who represents victims of foodborne illnesses, said the executive order “brought a big sigh of relief to CEOs across the country.” Marler also noted that the prospect of criminal penalties “did keep CEOs and people in the food business on their toes.” When the enforcement authority itself is subjected to structural dismantling by the defense, the resulting civil resolution reflects the new baseline of leverage rather than a balanced application of objective criteria.

Consequences and Future Enforcement Cascades

The substitution of civil penalties for criminal charges establishes a new deterrence calculus. A potential feedback loop emerges in the public-health domain: if criminal liability is structurally removed from the enforcement matrix, the cost of non-compliance becomes a calculable civil expense rather than an existential threat, potentially altering compliance investment thresholds in marginal cases. Companies facing comparable Food, Drug and Cosmetic Act exposure can cite the Abbott closure alongside the executive order in any future argument against indictment.

With the federal government explicitly retreating from criminal prosecution in this domain, the 31 states that joined the civil lawsuit may face pressure to independently pursue criminal enforcement under state consumer-protection and food-safety statutes to fill the federal vacuum, potentially producing a fragmented, multi-jurisdictional enforcement landscape.

The signal to watch is whether the consumer-protection office’s next high-profile matter survives internal review or follows Abbott’s path to civil resolution; either outcome will sharpen the doctrinal question of how “substantial public harm” is operationalized under the new policy frame. The next pressure point in the cascade is not a new indictment but the question of which objective criterion — inspection findings, the CDC’s genetic-testing record, the “knowingly” allegation preserved in the civil filing, or the executive order’s “substantial public harm” standard — will govern when the FDA flags a facility and the Justice Department declines to charge.

Integrative-Move Possibility

The party most exposed to a future integrative move — a resolution that could satisfy more interests on more sides than the current settlement — is the FDA. The mechanism to address this exposure is establishing joint civil-criminal referral criteria that align FDA inspection findings with the Justice Department’s “substantial public harm” threshold. This mechanism would address the current risk: the gap between the FDA’s enforcement expectations, anchored in its inspection record at Sturgis and its “serious concern” framing to lawmakers, and the charging thresholds the Justice Department now applies under the May 2025 order.

Unresolved Sourcing Gaps

The substantive terms of the Justice Department–Abbott civil settlement were not revealed; if disclosed in subsequent reporting, the framing of which party’s interest was most satisfied could be sharpened. The identification of the consumer-focused office steering the investigation is sourced only to people familiar with Filip’s discussions; the office’s name is not provided in the source material.

Analytical techniques used in this piece

This analysis applies the methods below. Each links to a short, plain-English explainer you can read and reuse.

Consequences & Sequels: Plays a decision forward to its first- and second-order consequences.
Interest Mapping: Separates parties’ stated positions from their underlying interests (Fisher & Ury).
Principled Negotiation: Works a negotiation from interests, options, and objective criteria rather than positions.
Supply & Demand: Price and quantity settle where what buyers want meets what sellers will offer.